For Those Of You Who Follow FDA Doings…
3
By Ed Silverman // September 10th, 2012 // 9:04
am
Watching the FDA may seem like so much ‘inside baseball’ to
the vast majority of people, but organizational changes can often have a
significant impact on how decisions are made, of course. So with this in mind,
we thought we would let you know about a few shifts inside the FDA’s Center for
Drug Evaluation and Research, which were announced late last week and are in the
process of being implemented.
Specifically, the Office of Generic Drugs is being elevated to a so-called ‘super office,’ which means the OGD will become an umbrella for other offices and report directly to CDER director Janet Woodcock. Other examples of ‘super offices’ include the Office of New Drugs and the Office of Surveillance and Epidemiology. OGD director Greg Geba will continue to head the office, according to the FDA announcement.
To read the rest of Ed Silverman's blog click here
Specifically, the Office of Generic Drugs is being elevated to a so-called ‘super office,’ which means the OGD will become an umbrella for other offices and report directly to CDER director Janet Woodcock. Other examples of ‘super offices’ include the Office of New Drugs and the Office of Surveillance and Epidemiology. OGD director Greg Geba will continue to head the office, according to the FDA announcement.
To read the rest of Ed Silverman's blog click here